RECRUITING

Paced Heart Rate Acceleration for Cardiac Conditioning

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A clinical trial of exercise-similar heart rate acceleration delivered via cardiac pacing vs. sham intervention in subjects at rest will be performed. The study population comprises subjects with guideline-directed medically managed left ventricular dysfunction due to ischemic or non-ischemic cardiomyopathy and an existing implantable cardioverter defibrillator or biventricular implantable cardioverter defibrillator. The purpose of the study is to understand how the heart rate pattern of exercise contributes to the considerable cardiac conditioning effects of exercise and estimate whether the pacing approach may have translational clinical applicability. Fifty-two subjects will be randomized, single-blinded, to either the pacing intervention or a sham intervention which they will receive once daily, 3 days/week for 6 weeks. Baseline symptoms and clinical test results will be compared to the same measures at 2 weeks, 4 weeks and 6 weeks of intervention/sham and at 3 months and one-year post-intervention. The primary endpoint will be the change in left ventricular ejection fraction from baseline in intervention vs. sham groups (mixed effects linear regression with time and treatment arm as fixed effects and pre-specified covariates of sex and cardiomyopathy type as random effects). Secondary endpoints will include changes in quality of life, 6-minute walk distance, cardiopulmonary exercise test (CPET) measures, daily activity and major adverse cardiac events (MACE) at 3 and 12 months between pacing and sham groups. A "dose-response" analysis of outcomes at 2, 4, and 6 weeks of the intervention vs. sham compared with baseline will be performed.

Official Title

A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection

Quick Facts

Study Start:2024-06-26
Study Completion:2028-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06332391

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Provision of signed and dated informed consent form
  2. * Stated willingness to comply with all study procedures and availability for the duration of the study
  3. * Male or female sex
  4. * Age 18 years or greater
  5. * Available transportation for study visits
  6. * Left ventricular ejection fraction \< or = 40% despite at least 3 months guideline-directed medial therapy
  7. * NYHA class II-III heart failure symptoms
  8. * Atrial-lead inclusive implantable cardioverter defibrillator or biventricular defibrillator in place \> 3 months
  9. * Intrinsic or biventricular paced QRS duration of \<= 120 milliseconds
  1. * Age \< 18 years
  2. * Inability to ambulate safely
  3. * Congenital or primary valve disease
  4. * Ongoing (not suppressed) atrial arrhythmias
  5. * Left ventricular thrombus
  6. * Severe peripheral arterial disease that limits mobility
  7. * Hospital admission for life-threatening condition (e.g. heart failure, stroke) in the past 3 months
  8. * Major surgery in the past 3 months or anticipated during the period of study
  9. * Ventricular pacing indication in the absence of biventricular pacing
  10. * Life expectancy \< 1 year
  11. * Hemodialysis
  12. * Hematocrit \< 30%
  13. * Severe chronic lung disease that limits activity or requires oxygen
  14. * Pregnancy
  15. * Implantable cardioverter defibrillator battery longevity \< 1 year
  16. * Vulnerable populations such as prisoners and institutionalized individuals

Contacts and Locations

Study Contact

Denice Hodgson-Zingman, MD
CONTACT
+1 319 384 2915
denice-zingman@uiowa.edu

Principal Investigator

Denice Hodgson-Zingman, MD
PRINCIPAL_INVESTIGATOR
University of Iowa

Study Locations (Sites)

University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States

Collaborators and Investigators

Sponsor: Denice Hodgson-Zingman, MD

  • Denice Hodgson-Zingman, MD, PRINCIPAL_INVESTIGATOR, University of Iowa

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-26
Study Completion Date2028-11-30

Study Record Updates

Study Start Date2024-06-26
Study Completion Date2028-11-30

Terms related to this study

Keywords Provided by Researchers

  • heart failure
  • exercise
  • heart rate
  • implantable defibrillator
  • cardiac conditioning
  • exercise tolerance
  • pacing
  • cardiac output
  • quality of life
  • walking distance

Additional Relevant MeSH Terms

  • Heart Failure, Systolic